A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

BACKGROUND: Conjunctival malignant melanoma (CMM) is a rare malignancy and in the advanced setting there is no effective treatment. In contrast, half of cutaneous melanomas have BRAF mutations and treatment with BRAF inhibitors is established for patients with disseminated disease. The most common f...

Descripción completa

Detalles Bibliográficos
Autores principales: Maleka, A., Åström, G., Byström, P., Ullenhag, G. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983009/
https://www.ncbi.nlm.nih.gov/pubmed/27520988
http://dx.doi.org/10.1186/s12885-016-2657-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983009/
https://www.ncbi.nlm.nih.gov/pubmed/27520988
http://dx.doi.org/10.1186/s12885-016-2657-7

Ejemplares similares